The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.
Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.
In this week's EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. And more.
Counterfeiters in Europe are displaying a fondness for mimicking high-priced Roche cancer drugs. For the second time in 5 months, authorities there have uncovered fakes, and the two cases appear not to be connected.
In this week's EuroBiotech Report, the search for the drug that can do to hepatitis B what Sovaldi does to hepatitis C led OnCure BioPharma to Sweden to strike a $150 million (€116 million) deal with NeuroVive Pharmaceutical. And more.
Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.
The European Union is betting heavily on graphene, a potential material of the future with several med tech applications, via a €1 billion ($1.3 billion) research fund dubbed the Graphene Flagship.
In this week's EuroBiotech Report, having spent much of 2014 touting the potential of its clinical-stage oncology candidates, AstraZeneca struck a deal with Redx Pharma to work on the next generation of cancer drugs. And more.
Pennsylvania-based West Pharmaceutical is again looking east for expansion. The maker of glass products for the pharma biz, which recently opened a plant in India, is now looking at adding a facility in Ireland that could run to €100 million.
Fresh off the sales of its interventional device unit to Boston Scientific, Bayer Healthcare is showing renewed interest in med tech via its startup accelerator.